Equities research analysts predict that Steris PLC (NYSE:STE) will report sales of $665.47 million for the current quarter, Zacks reports. Three analysts have provided estimates for Steris’ earnings, with the highest sales estimate coming in at $669.90 million and the lowest estimate coming in at $661.50 million. Steris reported sales of $646.77 million during the same quarter last year, which indicates a positive year-over-year growth rate of 2.9%. The firm is expected to announce its next quarterly earnings report on Tuesday, February 6th.

On average, analysts expect that Steris will report full year sales of $665.47 million for the current fiscal year, with estimates ranging from $2.60 billion to $2.62 billion. For the next year, analysts expect that the company will report sales of $2.72 billion per share, with estimates ranging from $2.71 billion to $2.74 billion. Zacks’ sales calculations are an average based on a survey of research firms that follow Steris.

Steris (NYSE:STE) last announced its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $0.94 EPS for the quarter, missing the Zacks’ consensus estimate of $0.95 by ($0.01). The company had revenue of $634.20 million during the quarter, compared to analysts’ expectations of $629.02 million. Steris had a return on equity of 11.49% and a net margin of 5.59%. Steris’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period last year, the firm earned $0.89 earnings per share.

STE has been the topic of a number of analyst reports. Zacks Investment Research cut Steris from a “buy” rating to a “sell” rating in a research note on Monday, November 6th. KeyCorp reissued a “buy” rating and set a $91.00 target price on shares of Steris in a research note on Tuesday, October 17th. Raymond James Financial boosted their target price on Steris from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, October 16th. Finally, TD Securities boosted their target price on Steris from C$14.00 to C$16.00 and gave the company a “buy” rating in a research note on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $79.50.

In related news, VP John Adam Zangerle sold 3,650 shares of Steris stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $88.00, for a total transaction of $321,200.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Michael J. Tokich sold 11,000 shares of Steris stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $92.00, for a total value of $1,012,000.00. Following the sale, the insider now owns 58,588 shares in the company, valued at $5,390,096. The disclosure for this sale can be found here. Insiders have sold 36,650 shares of company stock worth $3,315,200 over the last three months. Insiders own 2.55% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP bought a new stake in shares of Steris during the third quarter valued at approximately $284,000. Neuberger Berman Group LLC boosted its position in shares of Steris by 10.8% during the third quarter. Neuberger Berman Group LLC now owns 9,083 shares of the medical equipment provider’s stock valued at $803,000 after purchasing an additional 886 shares in the last quarter. California Public Employees Retirement System boosted its position in shares of Steris by 7.1% during the third quarter. California Public Employees Retirement System now owns 211,344 shares of the medical equipment provider’s stock valued at $18,683,000 after purchasing an additional 14,062 shares in the last quarter. Zions Bancorporation bought a new stake in shares of Steris during the third quarter valued at approximately $178,000. Finally, Vident Investment Advisory LLC bought a new stake in shares of Steris during the third quarter valued at approximately $952,000. Institutional investors own 89.40% of the company’s stock.

Steris (NYSE:STE) opened at $89.09 on Tuesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.80 and a quick ratio of 2.18. The company has a market capitalization of $7,585.82, a P/E ratio of 22.99 and a beta of 1.27. Steris has a 12 month low of $65.26 and a 12 month high of $93.39.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 20th. Stockholders of record on Wednesday, November 22nd will be paid a dividend of $0.31 per share. The ex-dividend date of this dividend is Tuesday, November 21st. This represents a $1.24 annualized dividend and a dividend yield of 1.39%. Steris’s dividend payout ratio (DPR) is presently 73.81%.

ILLEGAL ACTIVITY WARNING: This article was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.watchlistnews.com/zacks-analysts-anticipate-steris-plc-ste-will-post-quarterly-sales-of-665-47-million/1772832.html.

Steris Company Profile

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.

Get a free copy of the Zacks research report on Steris (STE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Steris (NYSE:STE)

Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.